Estrogen Receptor Agonist Market Size

  • Report ID: 4982
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Estrogen Receptor Agonist Market Size

Estrogen Receptor Agonist Market size was valued at USD 4.63 billion in 2024 and is set to exceed USD 12 billion by 2037, registering over 7.6% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of estrogen receptor agonist is evaluated at USD 5.21 billion.

This rise in market demand is anticipated to be driven by the growing prevalence of cardiovascular disease. According to the World Health Organization, with about 17.9 million deaths per year, cardiovascular diseases (CVDs) are the major cause of death globally. Hence, in order to treat this the demand for different treatments is growing among which estrogen receptor agonist is most preferred. Additionally, it has been proven to be one of the safer treatments for cardiovascular diseases.

Furthermore, women who are in their post-menopausal period are usually given estrogen receptor agonist treatment since they suffer various consequences such as a decline in the concentration of sex steroid hormones in the blood owing to a decline of ovary function. By 2030, the post-menopausal women are projected to reach 1.2 billion, globally.


Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 4982
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of estrogen receptor agonist is evaluated at USD 5.21 billion.

The estrogen receptor agonist market size was valued at USD 4.63 billion in 2024 and is set to exceed USD 12 billion by 2037, registering over 7.6% CAGR during the forecast period i.e., between 2025-2037. The market growth is driven by growing prevalence of osteoporosis, the rise in women suffering from PCOS, and the surge in the application of estrogen in asthma.

Asia Pacific industry is predicted to dominate majority revenue share by 2037, backed by growing geriatric population in this region.

The major players in the market are AstraZeneca, Eli Lilly and Company, ESTRIGENIX, Karo Healthcare AB, Merck KGaA, Vivesto AB, Oncternal Therapeutics, Pfizer Inc., Tocris Bioscience, Tokyo Chemical Industry Co., Ltd
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample